Food and Drug Administration

Gastrointestinal Drugs Advisory Committee

April 23, 2002

Slides

Lotronex (alosetron hydrochloride) Tablets, Dr. James Palmer, MD  pdf

GlaxoSmithKline  pdf

 Lotronex (alosetron HCI) Tablets Introduction, Dr. Victor Raczkowski, MD, FDA  htm  ppt

Lotronex: Clinical Trials, Thomas Permutt, FDA  htm  ppt

Lotronex Postmarketing Experience, Ann Corken Mackey, MPH, FDA  htm  ppt

Lotronex (alosetron HCI) Tablets Risk-Benefit Issues, Dr. Victor Raczkowski, MD, FDA  htm  ppt

Goals of a Lotronex Risk Management Program, Dr. Toni Piazza-Hepp, PharmD, FDA  htm ppt